These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26944921)

  • 1. Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker.
    Morrison K; Challita-Eid PM; Raitano A; An Z; Yang P; Abad JD; Liu W; Lortie DR; Snyder JT; Capo L; Verlinsky A; Aviña H; Doñate F; Joseph IB; Pereira DS; Morrison K; Stover DR
    Mol Cancer Ther; 2016 Jun; 15(6):1301-10. PubMed ID: 26944921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
    Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
    J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
    Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR
    Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.
    Willuda J; Linden L; Lerchen HG; Kopitz C; Stelte-Ludwig B; Pena C; Lange C; Golfier S; Kneip C; Carrigan PE; Mclean K; Schuhmacher J; von Ahsen O; Müller J; Dittmer F; Beier R; El Sheikh S; Tebbe J; Leder G; Apeler H; Jautelat R; Ziegelbauer K; Kreft B
    Mol Cancer Ther; 2017 May; 16(5):893-904. PubMed ID: 28292941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer.
    Mattie M; Raitano A; Morrison K; Morrison K; An Z; Capo L; Verlinsky A; Leavitt M; Ou J; Nadell R; Aviña H; Guevara C; Malik F; Moser R; Duniho S; Coleman J; Li Y; Pereira DS; Doñate F; Joseph IB; Challita-Eid P; Benjamin D; Stover DR
    Mol Cancer Ther; 2016 Nov; 15(11):2679-2687. PubMed ID: 27550944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Drug Delivery with an Integrin-Binding Knottin-Fc-MMAF Conjugate Produced by Cell-Free Protein Synthesis.
    Currier NV; Ackerman SE; Kintzing JR; Chen R; Filsinger Interrante M; Steiner A; Sato AK; Cochran JR
    Mol Cancer Ther; 2016 Jun; 15(6):1291-300. PubMed ID: 27197305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.
    Matsuzaki S; Serada S; Hiramatsu K; Nojima S; Matsuzaki S; Ueda Y; Ohkawara T; Mabuchi S; Fujimoto M; Morii E; Yoshino K; Kimura T; Naka T
    Int J Cancer; 2018 Mar; 142(5):1056-1066. PubMed ID: 29055044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.
    Serwotka-Suszczak AM; Sochaj-Gregorczyk AM; Pieczykolan J; Krowarsch D; Jelen F; Otlewski J
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28216573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.
    Phillips AC; Boghaert ER; Vaidya KS; Falls HD; Mitten MJ; DeVries PJ; Benatuil L; Hsieh CM; Meulbroek JA; Panchal SC; Buchanan FG; Durbin KR; Voorbach MJ; Reuter DR; Mudd SR; Loberg LI; Ralston SL; Cao D; Gan HK; Scott AM; Reilly EB
    Mol Cancer Ther; 2018 Apr; 17(4):795-805. PubMed ID: 29483208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy.
    Tong XM; Feng L; Suthe SR; Weng TH; Hu CY; Liu YZ; Wu ZG; Wang MH; Yao HP
    J Immunother Cancer; 2019 Sep; 7(1):250. PubMed ID: 31519211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.
    Ma D; Hopf CE; Malewicz AD; Donovan GP; Senter PD; Goeckeler WF; Maddon PJ; Olson WC
    Clin Cancer Res; 2006 Apr; 12(8):2591-6. PubMed ID: 16638870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LGR5-Targeted Antibody-Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence.
    Gong X; Azhdarinia A; Ghosh SC; Xiong W; An Z; Liu Q; Carmon KS
    Mol Cancer Ther; 2016 Jul; 15(7):1580-90. PubMed ID: 27207778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1.
    Thomas LJ; Vitale L; O'Neill T; Dolnick RY; Wallace PK; Minderman H; Gergel LE; Forsberg EM; Boyer JM; Storey JR; Pilsmaker CD; Hammond RA; Widger J; Sundarapandiyan K; Crocker A; Marsh HC; Keler T
    Mol Cancer Ther; 2016 Dec; 15(12):2946-2954. PubMed ID: 27671527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma.
    Nagaoka K; Bai X; Ogawa K; Dong X; Zhang S; Zhou Y; Carlson RI; Jiang ZG; Fuller S; Lebowitz MS; Ghanbari H; Wands JR
    Cancer Lett; 2019 May; 449():87-98. PubMed ID: 30768955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
    Kuo WY; Hsu HJ; Wu CY; Chen HS; Chou YC; Tsou YL; Peng HP; Jian JW; Yu CM; Chiu YK; Chen IC; Tung CP; Hsiao M; Lin CL; Wang YA; Wang AH; Yang AS
    MAbs; 2019 Jan; 11(1):153-165. PubMed ID: 30365359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry.
    Ekholm FS; Pynnönen H; Vilkman A; Pitkänen V; Helin J; Saarinen J; Satomaa T
    ChemMedChem; 2016 Nov; 11(22):2501-2505. PubMed ID: 27786414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes.
    Shor B; Kahler J; Dougher M; Xu J; Mack M; Rosfjord E; Wang F; Melamud E; Sapra P
    Clin Cancer Res; 2016 Jan; 22(2):383-94. PubMed ID: 26319086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.
    Wang X; Ma D; Olson WC; Heston WD
    Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.